Wire · opportunities
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
The FDA approved Eli Lilly's Mounjaro (tirzepatide) to reduce major cardiovascular events in adults with type 2 diabetes at high risk. This follows clinical trial results showing non-inferiority and 8% lower risk of cardiovascular death, heart attack, or stroke compared to Trulicity (dulaglutide).
This Wire brief sits within Fusion42's coverage of Medtech, and 20 sources have reported it between 28 Aug 2026 and 1 Sep 2026.
◆ ◆ The Wire takeaway
You face a new standard in cardiovascular risk reduction for type 2 diabetes treatment as Mounjaro sets a higher bar than existing therapies. This regulatory approval opens fresh market access opportunities for competing therapies and reshapes diabetic cardiovascular care.
◆ Coverage
20 sources · first reported 28 Aug 2026 · latest 1 Sep 2026
◆ Topics